NYSE:GKOSMedical Equipment
Glaukos (GKOS) Valuation After CMS J Code Milestone For Epioxa
Glaukos stock reacts to CMS reimbursement milestone for Epioxa
Glaukos (GKOS) is back in focus after the U.S. Centers for Medicare and Medicaid Services assigned a permanent HCPCS J-code to Epioxa for keratoconus treatment, a move that is expected to streamline reimbursement starting in July 2026.
See our latest analysis for Glaukos.
The CMS decision lands after a strong 30 day share price return of 17.74% and a 1 year total shareholder return of 29.50%, with momentum building on top of a...